Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma

Next Previous
Trial Profile

A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs AMG 232 (Primary) ; Carfilzomib; Dexamethasone; Dexamethasone; Lenalidomide
  • Indications Myeloma
  • Focus Adverse reactions

    • Most Recent Events

    • 11 Feb 2019 Status changed from suspended to recruiting.
    • 31 Aug 2018 Biomarkers information updated
    • 20 Jul 2018 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top